Trade

Indegene share price

Moderate risk
  • 22%Low risk
  • 22%Moderate risk
  • 22%Balanced risk
  • 22%High risk
  • 22%Extreme risk
  • 469.50(-0.78%)
    February 12, 2026 15:29:58 PM IST
    • NSE
    • BSE
  • Vol : 656.60 K (NSE + BSE)
    Last 20 day avg : 318.47 K

Indegene is trading -0.78% lower at Rs 469.50 as compared to its last closing price. Indegene has been trading in the price range of 472.90 & 468.10. Indegene has given -9.10% in this year & -1.28% in the last 5 days. Indegene has TTM P/E ratio 28.40 as compared to the sector P/E of 57.66.There are 6 analysts who have initiated coverage on Indegene. There are 1 analysts who have given it a strong buy rating & 1 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 102.90 Crores in its last quarter.Listed peers of Indegene include Delhivery (-0.14%), BLS International Services (-1.35%), Sagility (-3.23%).The Mutual Fund holding in Indegene was at 4.40% in 31 Dec 2025. The MF holding has increased from the last quarter. The FII holding in Indegene was at 11.48% in 31 Dec 2025. The FII holding has increased from the last quarter.

  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Explore on
Loading...
Key Metrics

Updated on Feb 12, 2026, 10:43 PM UTC

  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    0.04
    Lower than industry
  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    0.42
    Lower than industry
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    0.73
    Indicates undervaluation
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    -
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    -
  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    -
Price range
Day Range
Lowest
468.10
Highest
472.90
52 week range
Lowest
455.80
Highest
636.75
Indegene Peers
Return Comparison
Peers Comparison
Names
Technical ratingPrice%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Delhivery
Neutral
429.15-0.1432,131.67196.933.21-12.09
BLS International Services
Bearish
280.45-1.3511,547.2726.247.70.3116.43
Sagility
Moderately Bearish
48.46-3.2322,685.7144.822.930.1012.28
Swiggy
Neutral
337.35-1.4693,132.78-8.95-12.89
Urban Company
Bearish
121.15-1.9817,692.8475.9910.15-5.54
Mutual Fund Ownership
View all
Invesco India Technology Fund Regular Growth
NA
  • Amount Invested (Cr.) 11.57
  • % of AUM 3.50
Motilal Oswal Digital India Fund Regular Growth
NA
  • Amount Invested (Cr.) 26.15
  • % of AUM 3.29
SBI Long Term Advantage Fund Series VI Regular Plan Growth
NA
  • Amount Invested (Cr.) 6.01
  • % of AUM 2.14
Edelweiss Recently Listed IPO Fund Regular Plan Growth
NA
  • Amount Invested (Cr.) 16.82
  • % of AUM 1.88
SBI Innovative Opportunities Fund Regular Growth
NA
  • Amount Invested (Cr.) 125.45
  • % of AUM 1.70
Indegene Corporate Actions
View all
  • Board Meetings
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
Meeting DatePurpose
2026-01-29Quarterly Results & ESOP
2025-10-30Quarterly Results
2025-07-31Quarterly Results
2025-04-28Audited Results & Final Dividend
2025-01-30Quarterly Results & Others
About the company Indegene
  • IndustryBusiness Services
  • ISININE065X01017
  • BSE Code544172
  • NSE CodeINDGN
Indegene Limited is an India-based tech-native, life sciences commercialization company. The Company provides digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech, and medical devices companies. Its segments include Enterprise Medical Solutions, Enterprise Commercial Solutions, Brand Activation, and Others. The Enterprise Commercial Solutions business unit caters to the digital marketing operations of life sciences companies. The Enterprise Medical Solutions consolidates large-scale regulatory and medical operations for life sciences companies. The Brand Activation segment offers promotion of biopharmaceutical products and medical devices to HCPs for life sciences companies across channels. It provides customized marketing campaigns through a comprehensive portfolio of proprietary program offerings. Others mainly consist of consultancy and clinical business.
  • Management Info
  • Manish GuptaExecutive Chairman of the Board, Chief Executive Officer
  • Suhas PrabhuChief Financial Officer
  • Sanjay ParikhExecutive Vice President, Executive Director
  • Anand NijegalExecutive Vice President - Global Operations
  • Srishti KaushikCompliance Officer, Company Secretary
  • Viveksheel GhaiExecutive Vice President - Enterprise Commercial Solutions of Indegene, Inc.
  • Gaurav KapoorExecutive Vice President of Indegene, Inc.
  • Sameer LalSenior Vice President - Business Development of Indegene, Inc.
  • Rajesh NairNon-Executive Director, President of Indegene, Inc.
Indegene Share Price FAQs

Indegene is trading at 469.50 as on Thu Feb 12 2026 09:59:58. This is -0.78% lower as compared to its previous closing price of 473.20.

The market capitalization of Indegene is 11292.30 Cr as on Thu Feb 12 2026 09:59:58.

The average broker rating on Indegene is Hold. The breakup of analyst rating is given below -

  • 1 analysts have given a strong buy rating
  • 1 analysts have given a buy rating
  • 3 analysts have given a hold rating
  • 0.00 analysts have given a sell rating
  • 1 analysts have given a strong sell rating

The 52 wk high for Indegene is 636.75 whereas the 52 wk low is 455.80

Indegene can be analyzed on the following key metrics -

  • TTM P/E: 28.40
  • Sector P/E: 57.66
  • Dividend Yield: 0.42%
  • D/E ratio: -

Indegene reported a net profit of 406.70 Cr in 2025.

The Mutual Fund Shareholding was 4.40% at the end of 31 Dec 2025.